MedTrace Logo

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT05321420 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2025-10-16

No results posted yet for this study

Summary

This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.

Conditions

Interventions

DRUG

Placebo

placebo

DRUG

Pirfenidone

pirfenidone 801 mg TID

DRUG

Deupirfenidone

Deupirfenidone

Sponsors & Collaborators

Principal Investigators

  • Camilla Graham, MD · PureTech

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-22
Primary Completion
2024-10-15
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Chile
  • Colombia
  • Georgia
  • Greece
  • India
  • Malaysia
  • Mexico
  • Philippines
  • Romania
  • South Africa
  • South Korea
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05321420 on ClinicalTrials.gov